A Company Built on a Promise

Here for people today and tomorrow

Striving for excellence every day at Fresenius Kabi

All meaningful care comes down to people with the experience, expertise, and compassion to make a difference in the lives of those facing challenging situations. For us, care is a fundamental obligation, mission, and daily source of inspiration. It is the momentum that pushes us forward to help elevate the quality of life for both caregivers and those who need it most: critically and chronically ill patients. By providing essential medicines and technologies for infusion, transfusion, and clinical nutrition, we are helping advance the future of healthcare, making it even more accessible, reliable, and in tune with current and future needs.

young girl sleeping in intensive care unit


The face(s) of care

The Fresenius Group structure

Stronger together

We are proud to be part of the Fresenius Group with its more than 190,000 employees worldwide. Every day, we use all dedication, expertise, and passion to help advance healthcare opportunities and make a difference in people’s lives everywhere. Together, the Fresenius Group has a combined annual revenue of €22.3 billion with a positive financial forecast for the coming years.


Operating companies

Fresenius Kabi

Assisting critically and chronically ill patients with quality solutions for infusion, transfusion, and clinical nutrition.

2023 sales > €8.0 billion

Fresenius Helios

Making an impact as Europe’s leading private hospital operator with HELIOS and Quirónsalud hospitals.

2023 sales > 12.3 billion

Learn more about Fresenius Helios

Investment companies

Fresenius Medical Care

Helping people with chronic kidney failure live their best lives through comprehensive products and services.

Learn more about Fresenius Medical Care

Fresenius Vamed

Equipping global hospitals and healthcare facilities with the solutions they need for optimal outcomes.

Learn more about Fresenius Vamed

Consistent, long-term growth

A strong foundation to build on

As a company, we have continued to experience organic growth in all our key market sectors. Our broad industrial base, comprehensive range of system-critical healthcare products and leading market positions in clinical nutritionmedical technologies, and I.V. generic drugs. A clear financial strategy, combined with a high-performing team and a new leadership with revised governance ensures a profitable and productive future.

You are now leaving Fresenius Kabi Australia’s website, and are being redirected to an external website. Fresenius Kabi Australia takes no responsibility for the information contained on any sites that you will be accessing. The information that you are about to access may not comply with the Australian regulatory environment.

ACCEPT